Opinion|Videos|November 22, 2024
Optimal Dosing Strategies and Managing AEs
Panelists discuss how they dose talquetamab in clinical practice, comparing its administration schedule to other bispecific antibodies and addressing dosing-related challenges they encounter.
Advertisement
Episodes in this series
Video content above is promoted by the following;
- Briefly discuss your case details and share your initial thoughts.
- How are you currently dosing talquetamab?
- How does the dosing for talquetamab compare with other bispecifics?
- What are the challenges you are seeing?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5